Leiomyosarcoma - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Leiomyosarcoma - Pipeline Review, H1 2019’, provides an overview of the Leiomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

- The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects

- The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

ALX Oncology Inc

Apexigen Inc

AstraZeneca Plc

BeiGene Ltd

BioMed Valley Discoveries Inc

Cell Medica Ltd

Eli Lilly and Co

Exelixis Inc ...

Advenchen Laboratories LLC

ALX Oncology Inc

Apexigen Inc

AstraZeneca Plc

BeiGene Ltd

BioMed Valley Discoveries Inc

Cell Medica Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Incyte Corp

Karyopharm Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

PTC Therapeutics Inc

Vicore Pharma AB

Vicus Therapeutics LLC

Y-mAbs Therapeutics Inc

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leiomyosarcoma - Overview

Leiomyosarcoma - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leiomyosarcoma - Overview

Leiomyosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leiomyosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leiomyosarcoma - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

ALX Oncology Inc

Apexigen Inc

AstraZeneca Plc

BeiGene Ltd

BioMed Valley Discoveries Inc

Cell Medica Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Incyte Corp

Karyopharm Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

PTC Therapeutics Inc

Vicore Pharma AB

Vicus Therapeutics LLC

Y-mAbs Therapeutics Inc

Yooyoung Pharm Co Ltd

Leiomyosarcoma - Drug Profiles

(etodolac + propranolol hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anlotinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-005M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atezolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baltaleucel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bempegaldesleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

berzosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cabometyx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carboxyamidotriazole Orotate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Epstein-Barr Virus Associated Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-NT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenigacestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamiparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTC-596 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leiomyosarcoma - Dormant Projects

Leiomyosarcoma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Leiomyosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Leiomyosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2019

Leiomyosarcoma - Pipeline by ALX Oncology Inc, H1 2019

Leiomyosarcoma - Pipeline by Apexigen Inc, H1 2019

Leiomyosarcoma - Pipeline by AstraZeneca Plc, H1 2019

Leiomyosarcoma - Pipeline by BeiGene Ltd, H1 2019

Leiomyosarcoma - Pipeline by BioMed Valley Discoveries Inc, H1 2019

Leiomyosarcoma - Pipeline by Cell Medica Ltd, H1 2019

Leiomyosarcoma - Pipeline by Eli Lilly and Co, H1 2019

Leiomyosarcoma - Pipeline by Exelixis Inc, H1 2019

Leiomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Leiomyosarcoma - Pipeline by Incyte Corp, H1 2019

Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2019

Leiomyosarcoma - Pipeline by MedImmune LLC, H1 2019

Leiomyosarcoma - Pipeline by Merck & Co Inc, H1 2019

Leiomyosarcoma - Pipeline by Merck KGaA, H1 2019

Leiomyosarcoma - Pipeline by Nektar Therapeutics, H1 2019

Leiomyosarcoma - Pipeline by Novartis AG, H1 2019

Leiomyosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2019

Leiomyosarcoma - Pipeline by Pfizer Inc, H1 2019

Leiomyosarcoma - Pipeline by PTC Therapeutics Inc, H1 2019

Leiomyosarcoma - Pipeline by Vicore Pharma AB, H1 2019

Leiomyosarcoma - Pipeline by Vicus Therapeutics LLC, H1 2019

Leiomyosarcoma - Pipeline by Y-mAbs Therapeutics Inc, H1 2019

Leiomyosarcoma - Pipeline by Yooyoung Pharm Co Ltd, H1 2019

Leiomyosarcoma - Dormant Projects, H1 2019

Leiomyosarcoma - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Leiomyosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Leiomyosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports